Novo Nordisk A/S (ADR)
General ticker "NVO" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $320.3B (TTM average)
Novo Nordisk A/S (ADR) does not follow the US Stock Market performance with the rate: -12.4%.
Estimated limits based on current volatility of 1.3%: low 47.32$, high 48.60$
Factors to consider:
- Company pays dividends (semi-annually): last record date 2025-08-18, amount 0.58$ (Y2.42%)
- Total employees count: 3000 as of 2002
- Current price 40.0% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [80.05$, 120.56$]
- 2025-12-31 to 2026-12-31 estimated range: [83.06$, 123.88$]
Financial Metrics affecting the NVO estimates:
- Negative: with PPE of 27.8 at the end of fiscal year the price was very high
- Positive: Operating profit margin, % of 44.19 > 18.64
- Positive: Inventory ratio change, % of 0.29 <= 0.84
- Positive: 5.52 < Industry operating cash flow per share per price (median), % of 8.11
- Positive: -4.48 < Investing cash flow per share per price, % of -4.45
- Positive: Industry inventory ratio change (median), % of -0.66 <= -0.15
- Positive: Industry operating profit margin (median), % of 20.85 > 9.92
- Positive: Return on assets ratio (scaled to [-100,100]) of 17.82 > 6.04
- Positive: Interest expense per share per price, % of 0.06 <= 0.79
- Positive: 18.93 < Shareholder equity ratio, % of 30.80 <= 41.86
Short-term NVO quotes
Long-term NVO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | DKK176,954.00MM | DKK232,261.00MM | DKK290,403.00MM |
| Operating Expenses | DKK102,145.00MM | DKK129,687.00MM | DKK162,064.00MM |
| Operating Income | DKK74,809.00MM | DKK102,574.00MM | DKK128,339.00MM |
| Non-Operating Income | DKK-5,747.00MM | DKK2,100.00MM | DKK-1,148.00MM |
| Interest Expense | DKK378.00MM | DKK542.00MM | DKK1,640.00MM |
| R&D Expense | DKK24,047.00MM | DKK32,443.00MM | DKK48,062.00MM |
| Income(Loss) | DKK69,062.00MM | DKK104,674.00MM | DKK127,191.00MM |
| Taxes | DKK13,537.00MM | DKK20,991.00MM | DKK26,203.00MM |
| Profit(Loss)* | DKK55,525.00MM | DKK83,683.00MM | DKK100,988.00MM |
| Stockholders Equity | DKK83,486.00MM | DKK106,561.00MM | DKK143,486.00MM |
| Inventory | DKK24,388.00MM | DKK31,811.00MM | DKK40,849.00MM |
| Assets | DKK241,257.00MM | DKK314,486.00MM | DKK465,795.00MM |
| Operating Cash Flow | DKK78,887.00MM | DKK108,908.00MM | DKK120,968.00MM |
| Capital expenditure | DKK14,753.00MM | DKK38,896.00MM | DKK51,309.00MM |
| Investing Cash Flow | DKK-24,918.00MM | DKK-43,892.00MM | DKK-128,895.00MM |
| Financing Cash Flow | DKK-51,797.00MM | DKK-63,158.00MM | DKK8,735.00MM |
| Earnings Per Share** | DKK12.26 | DKK18.67 | DKK22.67 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.